摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Piperazin-1-ylpyrido[2,3-b]pyrazine | 946157-06-8

中文名称
——
中文别名
——
英文名称
6-Piperazin-1-ylpyrido[2,3-b]pyrazine
英文别名
6-piperazin-1-ylpyrido[2,3-b]pyrazine
6-Piperazin-1-ylpyrido[2,3-b]pyrazine化学式
CAS
946157-06-8
化学式
C11H13N5
mdl
——
分子量
215.258
InChiKey
ZDVQSXFNKILOFK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    53.9
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    6-Piperazin-1-ylpyrido[2,3-b]pyrazine 、 (3R,4aR,10aR)-6-methoxy-1-methyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-3-carboxylic acid, sodium salt 在 吡啶propylphosphonic anhydride 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以68%的产率得到[(3R,4aR,10aR)-6-methoxy-1-methyl-3,4,4a,5,10,10a-hexahydro-2H-benzo[g]quinolin-3-yl]-(4-pyrido[2,3-b]pyrazin-6-ylpiperazin-1-yl)methanone
    参考文献:
    名称:
    SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists
    摘要:
    The SAR of over 50 derivatives of octahydrobenzo[g]quinoline (obeline)-type somatostatin sst, receptor antagonist 1 is presented, focusing on the modification of its arylpiperazine moiety. sst(1) affinities in this series cover a range of five orders of magnitude with the best derivatives displaying subnanomolar sst, affinities and > 10,000-fold selectivities over the sst, receptor subtype as well as promising pharmacokinetic properties. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.078
  • 作为产物:
    描述:
    4-(5,6-diaminopyridine-2-yl)piperazine 、 草酸醛乙醇 为溶剂, 生成 6-Piperazin-1-ylpyrido[2,3-b]pyrazine
    参考文献:
    名称:
    SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists
    摘要:
    The SAR of over 50 derivatives of octahydrobenzo[g]quinoline (obeline)-type somatostatin sst, receptor antagonist 1 is presented, focusing on the modification of its arylpiperazine moiety. sst(1) affinities in this series cover a range of five orders of magnitude with the best derivatives displaying subnanomolar sst, affinities and > 10,000-fold selectivities over the sst, receptor subtype as well as promising pharmacokinetic properties. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.078
点击查看最新优质反应信息

文献信息

  • Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists
    作者:Thomas Troxler、Konstanze Hurth、Karl-Heinrich Schuh、Philippe Schoeffter、Daniel Langenegger、Albert Enz、Daniel Hoyer
    DOI:10.1016/j.bmcl.2010.01.063
    日期:2010.3
    Starting from non-peptidic sst(1)-selective somatostatin receptor antagonists, first compounds with mixed sst(1)/sst(3) affinity were identified by directed structural modifications. Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst(3)-subtype selective somatostatin antagonists based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety. These compounds can efficiently be synthesized and show promising PK properties in rodents. (C) 2010 Elsevier Ltd. All rights reserved.
  • SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists
    作者:Konstanze Hurth、Albert Enz、Philipp Floersheim、Conrad Gentsch、Daniel Hoyer、Daniel Langenegger、Peter Neumann、Paul Pfäffli、Dieter Sorg、Robert Swoboda、Annick Vassout、Thomas Troxler
    DOI:10.1016/j.bmcl.2007.04.078
    日期:2007.7
    The SAR of over 50 derivatives of octahydrobenzo[g]quinoline (obeline)-type somatostatin sst, receptor antagonist 1 is presented, focusing on the modification of its arylpiperazine moiety. sst(1) affinities in this series cover a range of five orders of magnitude with the best derivatives displaying subnanomolar sst, affinities and > 10,000-fold selectivities over the sst, receptor subtype as well as promising pharmacokinetic properties. (C) 2007 Elsevier Ltd. All rights reserved.
查看更多